These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 37808914)
1. Mucormycosis in 2023: an update on pathogenesis and management. Alqarihi A; Kontoyiannis DP; Ibrahim AS Front Cell Infect Microbiol; 2023; 13():1254919. PubMed ID: 37808914 [TBL] [Abstract][Full Text] [Related]
9. Finegoldia magna and Mucorales molds co-infection in a severe case of SARS-CoV-2 disease. Hristova R; Vlahova A; Christova M; Stamatov K; Stanimirov P J Infect Dev Ctries; 2023 Sep; 17(9):1231-1236. PubMed ID: 37824356 [TBL] [Abstract][Full Text] [Related]
10. [Mucormycosis: Current and future management perspective]. Martín Gómez MT; Salavert Lletí M Rev Iberoam Micol; 2021; 38(2):91-100. PubMed ID: 34144835 [TBL] [Abstract][Full Text] [Related]
11. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. Liu M; Spellberg B; Phan QT; Fu Y; Fu Y; Lee AS; Edwards JE; Filler SG; Ibrahim AS J Clin Invest; 2010 Jun; 120(6):1914-24. PubMed ID: 20484814 [TBL] [Abstract][Full Text] [Related]
12. Association of Serum Iron Studies in COVID Associated Mucormycosis with Stage of the Disease. Rao C; R M J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443509 [TBL] [Abstract][Full Text] [Related]
14. Lactoferrin, a potential iron-chelator as an adjunct treatment for mucormycosis - A comprehensive review. Singh A; Ahmad N; Varadarajan A; Vikram N; Singh TP; Sharma S; Sharma P Int J Biol Macromol; 2021 Sep; 187():988-998. PubMed ID: 34324905 [TBL] [Abstract][Full Text] [Related]
15. Szebenyi C; Gu Y; Gebremariam T; Kocsubé S; Kiss-Vetráb S; Jáger O; Patai R; Spisák K; Sinka R; Binder U; Homa M; Vágvölgyi C; Ibrahim AS; Nagy G; Papp T mBio; 2023 Feb; 14(1):e0338622. PubMed ID: 36625576 [TBL] [Abstract][Full Text] [Related]
16. Host-iron assimilation: pathogenesis and novel therapies of mucormycosis. Ibrahim AS Mycoses; 2014 Dec; 57 Suppl 3(0 3):13-7. PubMed ID: 25178879 [TBL] [Abstract][Full Text] [Related]
17. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Rudramurthy SM; Hoenigl M; Meis JF; Cornely OA; Muthu V; Gangneux JP; Perfect J; Chakrabarti A; Mycoses; 2021 Sep; 64(9):1028-1037. PubMed ID: 34133816 [TBL] [Abstract][Full Text] [Related]
18. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options. Riley TT; Muzny CA; Swiatlo E; Legendre DP Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416 [TBL] [Abstract][Full Text] [Related]
19. Review on Mucormycosis: Pathogenesis, Epidemiology, Microbiology and Diagnosis. Sharma A; Alam MA; Dhoundiyal S; Sharma PK Infect Disord Drug Targets; 2024; 24(1):e220823220209. PubMed ID: 37608614 [TBL] [Abstract][Full Text] [Related]
20. Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. Pana ZD; Seidel D; Skiada A; Groll AH; Petrikkos G; Cornely OA; Roilides E; BMC Infect Dis; 2016 Nov; 16(1):667. PubMed ID: 27832748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]